Skip to Content

8-MOP (methoxsalen) Disease Interactions

There are 3 disease interactions with 8-MOP (methoxsalen):

Major

Methoxsalen (Includes 8-MOP) ↔ aphakia

Severe Potential Hazard, High plausibility. Applies to: Aphakia

The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with aphakia. The potential for retinal damage with PUVA (psoralen and UVA photochemotherapy) may be increased due to the absence of lenses.

References

  1. "Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc, Costa Mesa, CA.
Major

Methoxsalen (Includes 8-MOP) ↔ photosensitivity states

Severe Potential Hazard, High plausibility. Applies to: Lupus Erythematosus, Porphyria

The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states. Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly. Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.

References

  1. "Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc, Costa Mesa, CA.
  2. "Product Information. Oxsoralen Lotion (methoxsalen topical)." ICN Pharmaceuticals, Costa Mesa, CA.
Major

Methoxsalen (Includes 8-MOP) ↔ skin cancer

Severe Potential Hazard, High plausibility. Applies to: History - Skin Cancer, Skin Cancer

The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma. PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma. Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer. If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored. The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.

References

  1. "Product Information. Oxsoralen (methoxsalen)." ICN Pharmaceuticals Inc, Costa Mesa, CA.
  2. "Product Information. Oxsoralen Lotion (methoxsalen topical)." ICN Pharmaceuticals, Costa Mesa, CA.

8-MOP (methoxsalen) drug interactions

There are 102 drug interactions with 8-MOP (methoxsalen)

8-MOP (methoxsalen) alcohol/food interactions

There is 1 alcohol/food interaction with 8-MOP (methoxsalen)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide